Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: PEMBROLIZUMAB, . Treffer: 13

2023

Lindner, AK; Martowicz, A; Untergasser, G; Haybaeck, J; Compérat, E; Kocher, F; Seeber, A; Thurnher, M; Pichler, R CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival after Surgery of Localised Renal Cell Carcinoma.
Cancers (Basel). 2023; 15(4): Doi: 10.3390/cancers15041001 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2022

Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Koeberle, D; Welslau, M; Sanoyan, DA; Maas, C; Uhlig, J; Fenchel, K; Greil, R; VON, DER, Heyde, E; Agocs, GR; Weide, R; Schwager, M; Reichenbach, F; Modest, DP; Fritsch, R Retrospective Analysis of Treatment Pathways in Patients With BRAF^V600E-mutant Metastatic Colorectal Carcinoma - MORSE^CRC.
Anticancer Res. 2022; 42(10):4773-4785 Doi: 10.21873/anticanres.15982
Web of Science PubMed FullText FullText_MUG

 

Petru, E Endometrial cancer: news from ASCO
MEMO-MAG EUR MED ONC. 2022; Doi: 10.1007/s12254-022-00844-3
Web of Science FullText FullText_MUG

 

Schlintl, V; Huemer, F; Rinnerthaler, G; Melchardt, T; Winder, T; Reimann, P; Riedl, J; Amann, A; Eisterer, W; Romeder, F; Piringer, G; Ilhan-Mutlu, A; Woll, E; Greil, R; Weiss, L Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort
BMC CANCER. 2022; 22(1): 51 Doi: 10.1186/s12885-021-09115-6 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Suppan, C ESMO 2021-my top three abstracts in breast cancer
MEMO-MAG EUR MED ONC. 2022; Doi: 10.1007/s12254-022-00810-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2021

Farinazzo, E; Zelin, E; Agozzino, M; Papa, G; Pizzichetta, MA; di, Meo, N; Zalaudek, I Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma.
Melanoma Res. 2021; 31(6): 582-585. Doi: 10.1097/CMR.0000000000000776
Web of Science PubMed FullText FullText_MUG

 

Geiger-Gritsch, S; Olschewski, H; Kocher, F; Wurm, R; Absenger, G; Flicker, M; Hermann, A; Heininger, P; Fiegl, M; Zechmeister, M; Endel, F; Wild, C; Pall, G Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer : A retrospective Austrian multicenter study.
Wien Klin Wochenschr. 2021; 133(21-22):1122-1130 Doi: 10.1007/s00508-021-01940-w
Web of Science PubMed FullText FullText_MUG

 

Jabkowski, J; Loidl, A; Auinger, B; Kehrer, H; Sepp, N; Pichler, R Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report.
Front Immunol. 2021; 12: 606056 Doi: 10.3389/fimmu.2021.606056 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Wagner, NB; Lenders, MM; Kühl, K; Reinhardt, L; André, F; Dudda, M; Ring, N; Ebel, C; Stäger, R; Zellweger, C; Lang, R; Paar, M; Gussek, P; Richtig, G; Stürmer, SH; Kimeswenger, S; Oellinger, A; Forschner, A; Leiter, U; Weide, B; Gassenmaier, M; Schraag, A; Klumpp, B; Hoetzenecker, W; Berking, C; Richtig, E; Ziemer, M; Mangana, J; Terheyden, P; Loquai, C; Nguyen, VA; Gebhardt, C; Meier, F; Diem, S; Cozzio, A; Flatz, L; Röcken, M; Garbe, C; Eigentler, TK Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
J Immunother Cancer. 2021; 9(5): e002350 Doi: 10.1136/jitc-2021-002350 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Carlino, MS; Long, GV; Schadendorf, D; Robert, C; Ribas, A; Richtig, E; Nyakas, M; Caglevic, C; Tarhini, A; Blank, C; Hoeller, C; Bar-Sela, G; Barrow, C; Wolter, P; Zhou, H; Emancipator, K; Jensen, EH; Ebbinghaus, S; Ibrahim, N; Daud, A Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
EUR J CANCER. 2018; 101(3): 236-243. Doi: 10.1016/j.ejca.2018.06.034 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gandhi, L; Rodríguez-Abreu, D; Gadgeel, S; Esteban, E; Felip, E; De Angelis, F; Domine, M; Clingan, P; Hochmair, MJ; Powell, SF; Cheng, SY; Bischoff, HG; Peled, N; Grossi, F; Jennens, RR; Reck, M; Hui, R; Garon, EB; Boyer, M; Rubio-Viqueira, B; Novello, S; Kurata, T; Gray, JE; Vida, J; Wei, Z; Yang, J; Raftopoulos, H; Pietanza, MC; Garassino, MC; KEYNOTE-189 Investigators Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med. 2018; 378(22): 2078-2092. Doi: 10.1056/NEJMoa1801005
Web of Science PubMed FullText FullText_MUG

 

2017

Petrella, TM; Robert, C; Richtig, E; Miller, WH; Masucci, GV; Walpole, E; Lebbe, C; Steven, N; Middleton, MR; Hille, D; Zhou, W; Ibrahim, N; Cebon, J Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
EUR J CANCER. 2017; 86(5): 115-124. Doi: 10.1016/j.ejca.2017.08.032 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Robert, C; Schachter, J; Long, GV; Arance, A; Grob, JJ; Mortier, L; Daud, A; Carlino, MS; McNeil, C; Lotem, M; Larkin, J; Lorigan, P; Neyns, B; Blank, CU; Hamid, O; Mateus, C; Shapira-Frommer, R; Kosh, M; Zhou, H; Ibrahim, N; Ebbinghaus, S; Ribas, A; KEYNOTE-006 investigators Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2015; 372(26):2521-2532 Doi: 10.1056/NEJMoa1503093 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum